Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 38.48M 27.71M 23.98M 22.53M 20.49M 2.65B 39.19M 264M 103M 1.33B 104M 102M 4.42B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 38.25M 27.55M 23.83M 22.39M 20.37M 2.63B 38.95M 262M 102M 1.32B 104M 101M 4.39B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
1 day-5.88%
1 week+6.67%
Current month+23.08%
1 month+14.29%
3 months+68.42%
6 months+14.29%
Current year-5.88%
1 week 0.16
Extreme 0.155
0.18
1 month 0.12
Extreme 0.125
0.18
Current year 0.07
Extreme 0.07
0.19
1 year 0.07
Extreme 0.07
0.2
3 years 0.04
Extreme 0.035
0.36
5 years 0.04
Extreme 0.035
0.36
10 years 0.04
Extreme 0.035
0.36
Manager TitleAgeSince
Chief Executive Officer - 2019-06-30
Director of Finance/CFO - 2022-08-16
Chief Tech/Sci/R&D Officer - 2024-09-16
Director TitleAgeSince
Director/Board Member - 2017-12-05
Director/Board Member - 2019-06-30
Chairman - 2025-04-29
Date Insider Type Main position Quantity % Market Cap.
3/6/26 Option

Director

41,842 0.0234%
3/6/26 Option 800,000 0.4480%
8/20/25 Option 1,120,000 0.6981%
Change 5-day change 1-year change 3-year change Capi.($)
-5.88%+6.67%-5.88%+166.67% 27.6M
-2.25%-0.99%+78.68%+123.40% 1,078B
-0.66%+1.31%+49.27%+49.76% 632B
-0.54%+2.29%+23.82%+63.92% 443B
-1.99%-2.63%+42.21%+33.92% 356B
-1.05%-2.19%+25.55%+34.88% 289B
-2.12%-3.29%+0.14%+3.90% 245B
-0.63%+2.56%+43.51%+58.17% 226B
-1.19%+0.37%-9.57%-52.51% 204B
+0.16%+5.73%+15.17%+72.95% 171B
Average -1.10%+2.62%+26.29%+55.50% 364.37B
Weighted average by Cap. -0.09%+1.30%+43.75%+63.35%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.4 0.03 0.03 1.34
Net income -1.71M -1.23M -1.06M -999K -909K -117M -1.74M -11.72M -4.57M -58.91M -4.62M -4.52M -196M -3.53M -2.54M -2.2M -2.07M -1.88M -243M -3.6M -24.24M -9.46M -122M -9.56M -9.35M -406M
Net Debt -113K -81.12K -70.18K -65.94K -59.98K -7.74M -115K -773K -302K -3.89M -305K -298K -12.93M -231K -166K -144K -135K -123K -15.85M -235K -1.58M -618K -7.96M -624K -610K -26.47M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume
26-08-14 CA$0.1600 -5.88% 104,310
26-08-13 CA$0.1700 +3.03% 231,500
26-08-12 CA$0.1650 +3.13% 431,509
26-08-11 CA$0.1600 -3.03% 113,467
26-08-10 CA$0.1650 +6.45% 893,591

Annual profits - Rate of surprise